Clinical Trial Results:
Influence of insulin Levemir on endothelial function in type 2 diabetes mellitus.
A prospective case-control study.
Summary
|
|
EudraCT number |
2006-005175-18 |
Trial protocol |
AT |
Global end of trial date |
30 Sep 2008
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Aug 2022
|
First version publication date |
11 Aug 2022
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
151610/06
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medical University Innsbruck
|
||
Sponsor organisation address |
Christoph-Probst-Platz 1, Innrain 52, Innsbruck, Austria, 6020
|
||
Public contact |
Univ.- Prof. Dr. Josef Patsch, University Hospital for Internal Medicine I, Anichstrasse 35, 6020 Innsbruck, +43 (0)512/504-23539 , viktoria.koc@tirol-kliniken.at
|
||
Scientific contact |
Univ.- Prof. Dr. Josef Patsch, University Hospital for Internal Medicine I, Anichstrasse 35, 6020 Innsbruck, +43 (0)512/504-23539 , viktoria.koc@tirol-kliniken.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Sep 2008
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Sep 2008
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The overall goal of the present trial is to study the influence of insulin Levemir treatment on the endothelial function of patients with type 2 DM by noninvasive measurement of flow-mediated ndothelium-dependent dilation (EDD) of the brachial artery.
|
||
Protection of trial subjects |
N/A
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Sep 2007
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 99999
|
||
Worldwide total number of subjects |
99999
|
||
EEA total number of subjects |
99999
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
99999
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
No patients were recruited for this trial. "99999" is a value for 0 participants. | ||||||
Pre-assignment
|
|||||||
Screening details |
N/A | ||||||
Period 1
|
|||||||
Period 1 title |
Treatment (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Levemir | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Levemir
|
||||||
Investigational medicinal product code |
|||||||
Other name |
Insulindetemir
|
||||||
Pharmaceutical forms |
Injection
|
||||||
Routes of administration |
Subcutaneous use
|
||||||
Dosage and administration details |
N/A
|
||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
No patients were recruited for this trial. "99999" is a value for 0 participants. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Levemir
|
||
Reporting group description |
- |
|
|||||||||
End point title |
Levemir [1] | ||||||||
End point description |
|||||||||
End point type |
Primary
|
||||||||
End point timeframe |
N/A
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No patients were enrolled in this trial, therefore no satistical analysis was performed. |
|||||||||
|
|||||||||
Notes [2] - "99999" is a value for 0 participants. |
|||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
28.09.2007-30.09.2008
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
CTCAE | ||
Dictionary version |
3.0
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No patients were enrolled in this trial, therefore no AEs or SAEs were observed. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
No patients were enrolled in this trial. "99999" is a value for 0 participants. |